Heck Capital Advisors LLC Purchases 296 Shares of Johnson & Johnson $JNJ

Heck Capital Advisors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.8% in the second quarter, Holdings Channel reports. The firm owned 2,795 shares of the company’s stock after buying an additional 296 shares during the quarter. Heck Capital Advisors LLC’s holdings in Johnson & Johnson were worth $427,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.5%

Johnson & Johnson stock opened at $189.75 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm’s fifty day moving average price is $177.49 and its two-hundred day moving average price is $163.37. The firm has a market capitalization of $456.98 billion, a price-to-earnings ratio of 20.29, a price-to-earnings-growth ratio of 2.41 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $190.22.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Bank of America lifted their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $189.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.